OmniAb Inc.
3.25
0.06 (1.88%)
At close: Jan 15, 2025, 12:49 PM
undefined%
Bid 3.24
Market Cap 392.69M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.62
PE Ratio (ttm) -5.23
Forward PE n/a
Analyst Buy
Ask 3.25
Volume 120,490
Avg. Volume (20D) 460,116
Open 3.30
Previous Close 3.19
Day's Range 3.23 - 3.37
52-Week Range 3.19 - 6.55
Beta undefined

About OABI

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been geneti...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 30, 2021
Employees 106
Stock Exchange NASDAQ
Ticker Symbol OABI

Analyst Forecast

According to 4 analyst ratings, the average rating for OABI stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 177.35% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

OmniAb Inc. is scheduled to release its earnings on Mar 19, 2025, during market hours.
Analysts project revenue of $11.27M, reflecting a 133.72% YoY growth and earnings per share of -0.11, making a -21.43% decrease YoY.
2 months ago · Source
-9.35%
OmniAb shares are trading lower after the company ... Unlock content with Pro Subscription